Osteotech, Inc. 

(Public, NASDAQ:OSTE)   Watch this stock   
Find more results for OSTE
Nov 6, 2009
Q3 2009 Financial Results Conference Call
Nov 5, 2009
Q3 2009 Earnings Release
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin -8.31% 2.12%
Operating margin -7.55% 2.48%
EBITD margin - 7.92%
Return on average assets -6.30% 1.78%
Return on average equity -9.59% 2.72%
Employees 331 -

Address

51 James Way
Eatontown, NJ 07724
United States - Map
+1-732-5422800 (Phone)
+1-732-5429312 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Osteotech, Inc. discussions

  View all discussions »

Description

Osteotech, Inc. (Osteotech) is a medical technology company that develops, processes and distributes biologic products focused on the orthopedic, neurosurgical and oral/maxillofacial surgery markets. The Company is focused on creating technology platforms that provides a variety of procedural specific biologic products to address the changing needs of orthopedics and healthcare in general. The Company’s products focus on biologic solutions for regenerative medicine that can alleviate pain, promote healing and restore functions. Osteotech has five technology platforms: Demineralized Bone Matrix (DBM), Hybrid/Synthetic, Human Collagen Technology, Traditional Tissue and Spinal Allograft.

Officers and directors

Kenneth P. Fallon III
Chairman of the Board
Age: 70
Bio & Compensation - Reuters
Sam Owusu-Akyaw
President, Chief Executive Officer, Director
Age: 56
Bio & Compensation - Reuters
Mark H. Burroughs
Chief Financial Officer, Executive Vice President
Age: 48
Bio & Compensation - Reuters
Robert M. Wynalek
President - Domestic
Age: 49
Bio & Compensation - Reuters
Robert W. Honneffer
Executive Vice President - Global Operations
Age: 57
Bio & Compensation - Reuters
Stephen S. Galliker CPA
Director
Age: 62
Bio & Compensation - Reuters
Robert J. Palmisano
Director
Age: 64
Bio & Compensation - Reuters
James M. Shannon
Director
Age: 57
Bio & Compensation - Reuters
Cato T. Laurencin M.D., Ph.D.
Independent Director
Age: 50
Bio & Compensation - Reuters